Showing results (261-270 of 332) with videos related to

Sort By:
Pageof 34
Blood Neoplasia|April 6, 2026
Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT studyEduardo Rodríguez-Arbolí, Allain-Thibeault Ferhat, Anna Maria Raiola, et al.
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Bone Marrow Transplantation|February 5, 2025
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamideAlexandros Spyridonidis, Myriam Labopin, Bipin P Savani, et al.
Cancers|February 11, 2023
Novel Candidate <i>loci</i> and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome SequencingCristina Andrés-Zayas, Julia Suárez-González, María Chicano-Lavilla, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Frontiers in Immunology|June 7, 2021
Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic TransplantRebeca Bailén, José Luis Vicario, Laura Solán, et al.
Clinical Case Reports|January 14, 2022
Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucelReyes Maria Martín-Rojas, Ignacio Gómez-Centurión, Rebeca Bailén, et al.
Annals of Hematology|November 3, 2020
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantationRebeca Bailén, Mi Kwon, María Jesús Pascual-Cascón, et al.
Bone Marrow Transplantation|November 25, 2025
Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMTJaime Sanz, Allain-Thibeault Ferhat, Anna Maria Raiola, et al.
The New England Journal of Medicine|September 18, 2024
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseDaniel Wolff, Corey Cutler, Stephanie J Lee, et al.
Pageof 34